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THE SCYLLA AND CHARYBDIS OF
ORAL ANTICOAGULANT TREATMENT
TREATMENT with oral anticoagulant drugs (i.e.,coumarin derivatives such äs warfarin) is effective
in the prevention of venous and arterial thromboem-
bolism. In patients with atrial fibrillation, anticoagu-
lation reduces the risk of stroke by 70 percent.1 The
principal problem with anticoagulation is the vari-
ability of the effect of coumarin derivatives on the
hemostatic System; patients may require very differ-
ent doses (up to 10-fold differerices) to reach the
same level of anticoagulation, and the required dose
may also vary over time in an individual patient.
Siiice underanticoagulation is ineffective and overan-
ticoagulation may lead to hemorrhage, anticoagulant
treatment needs to be monitored and adjusted to
steer safely between the Scylla of thrombosis and the
Charybdis of bleeding. The realization that such
monitoring requires experience and specialization
led to the emergence of anticoagulation clinics äs
early äs the 1950s in the Netherlands, and more re-
cently in Italy, Canada, and the United States. There
is no doubt that monitoring by specialized anticoag-
ulation clinics improves the quality of carc and re-
duces the rate of complications; when adequately
controlled, oral anticoagulant therapy is effective
and safe.2
Two major issues remain to be resolved. First,
what intensity of anticoagulation should be the goal
for each of the indications for this therapy? The
introduction of the international normalized ratio
(INR),3 an international Standard for measuring the
anticoagulant effect of therapy that allows prothrom-
bin-time ratios measured with different thrombo-
plastins to be compared, has made it possible to per-
form and intcrprct studies of the optimal intensity
of anticoagulant therapy. The second question is
whether it is advantageous to use other antithrom-
botic drugs, notably aspirin, either alone or in com-
bination with oral anticoagulants, in the treatment
of arterial disease. Both questions arise from the de-
sire to obtain the best benefit-risk profile: to prevent
thrombosis äs effectively äs possible while causing äs
little bleeding äs possible.
In this issue of the Journal, Hylek and colleagues4
report on their investigation of the optimal intensity
of oral anticoagulation to prevent ischemic stroke in
patients with nonrheumatic atrial fibrillation. They
studied 74 patients with atrial fibrillation who had
had a stroke even though thcy werc receiving antico-
agulant therapy, and compared the intensity of anti-
coagulation (äs indicated by the INR) with that in a
random sample of patients who were receiving anti-
coagulant therapy for atrial fibrillation but who did
not have strokes. The risk of stroke was minimal at
INRs of 2.0 or higher. This risk incrcased sharply
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when the INR feil bclow 2.0, whereas tlierc was no
further protection with more intense anticoagulation.
Hylek and coworkers uscd a case-control ap-
proach, which has the advantage that the inclusion
of evcn a relatively small number of case patients can
yield the pcison-time equivalent of a very largc fol-
low-up study. It is important to note that with this
approach a cross section of patients with out stroke
should be sampled äs controls (äs Hylek et al. did),
rather than a cross section of their INR values, since
under- and overanticoagulated patients are usually
seen morc frequently in the clinic than are patients
with a stable degree of anticoagulation. Sampling
patients and examining their previous INR vaiues
has been calied the "cross section of the files" meth-
od,5 which takes into account the different intervals
for monitoring different patients. Dcspite its advan-
tages, the case-control approach has two disadvan-
tages. First, the results apply only to one side of the
spcctrum — in this case, to ischemic strokes and not
to hemorrhagic complications. And second, only
relative risks can be estimated and not absolute rates
of disease. So it cannot be directly infcrred from the
study by Hylek and colleagues which intensity of an-
ticoagulant treatment is associated with the lowest
risk of all untoward events. Several other reports make
such estimates possible, however.
In two previous studies, INR-specific rates of com-
plications were calculated according to a person-
time method within a cohort.6 The first study was
conductcd among patients with mechanical heart
valves who were routinely treated in four Dutch an-
ticoagulation clinics.7 The second was the European
Atrial Fibrillation Trial, a study of secondary preven-
tion in patients with atrial fibrillation who had pre-
viously had a minor stroke.8 The latter study, al-
though it included far fewer patients with strokes
than the study by Hylek et al., reported very similar
results with respect to the risk of stroke, which in-
creased at INR values below 2.0. The risk of hem-
orrhage increased at INRs above 4.5. For patients
with mechanical heart valves, the optimal level of an-
ticoagulation was slightly more intense; the inci-
dence of thromboembolism increased at INR values
below 2.5, and bleeding increased at values of 4.5 or
higher.7
In patients with atrial fibrillation, therefbre, the
INR should be maintained at all times between 2.0
and 4.5, and in patients with mechanical heart valves
it should be held between 2.5 and 4.5. With some
margin of safety built in at both ends, reasonable
target ranges for the INR are 2.5 to 3.5 (target, 3.0)
for patients with atrial fibrillation, and 3.0 to 4.0
(target, 3.5) for those with mechanical heart valves.
Interestingly, researchers have pinpointed these op-
timal levels through observational studies (both fol-
low-up and case-control) and not by means of ran-
domized trials. Because of the variability of the effect
of anticoagulant therapy, the optimal intensity of an-
ticoagulation cannot be easily studied in a random-
ized fashion.6 Moreovcr, even if the variability of ef-
fect were overcome by including very large numbers
of patients, an endless serics of randomized trials,
cach with a slightly different target INR, would be re-
quircd.
As Hylek and coauthors point out, these accumu-
lating data put an end to the push for ever lower in-
tensities of anticoagulation, and indeed a study with
a lower target (the Stroke Prcvention in Atrial Fibril-
lation III trial, with a target INR ränge of 1.2 to
1.5) was recently terminated prcmaturcly becausc
there was too littie clinical effect of treatment.9
Aspirin is an antithrombotic agent that inhibits
platelet aggregation. It prcvents thrombosis but ap-
pears to be less effective than oral anticoagulation
for virtually all indications, including the prevcntion
of thromboembolism in patients with atrial fibrilla-
tion. Its great advantages are that no monitoring is
needed and that it is associated with a lower risk
of hemorrhage than are oral anticoagulants. Several
studies have compared aspirin with warfarin, and to-
gether with other studies of these agents, they point
to a higher overall rcduction in the risk of cardiovas-
cular events (including both thromboembolism and
hemorrhage) with oral anticoagulants.10"12
It is still unclear whether the risk of hemorrhage
increases with age,7-13 but elderly patients with atrial
fibrillation are certainly at the highest risk for is-
chemic stroke and will benefit most from oral anti-
coagulant therapy. The first choice for antithrom-
botic therapy in all patients with atrial fibrillation is
therefore an oral anticoagulant agent. Treatment
should be monitored by specialized anticoagulation
clinics to minimize risks. Only if good control of the
intensity of anticoagulation is not possible, or for
the exceptional patient who has a high risk of bleed-
ing or whose compliance is expected to be poor, may
aspirin be the drug of choice.
Several studies are under way, both in patients
with atrial fibrillation and in patients with mechan-
ical heart valves, to investigate the efficacy of the
combination of oral anticoagulants and aspirin. The
hypothesis that anticoagulation at a moderate inten-
sity combined with Inhibition of platelet aggrega-
tion may have beneficial clinical effects is worthy of
testing. So far, however, combination therapy has
not been found to be superior to well-controlled an-
ticoagulant treatment.9'14"16 Therefore, the time has
not yet arrived for this combination therapy to be
used in routine clinical practice.
The optimal intensity of oral anticoagulation that
can now be recommended for various indications
takes the form of ranges around target levels. We still
need to increase the proportion of INR values that
are actually within these optimal ranges. The next
step will be to define individualized levels of antico-
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agulation for patients with differcnt risk profiles, a
stcp that may evcntually lead to individually custom-
ized anticoagulant treatment.
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